Evotec (NASDAQ:EVO) & Qiagen (NYSE:QGEN) Critical Comparison

Evotec (NASDAQ:EVO) and Qiagen (NYSE:QGEN) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation and dividends.

Insider and Institutional Ownership

5.8% of Evotec shares are owned by institutional investors. Comparatively, 70.0% of Qiagen shares are owned by institutional investors. 1.0% of Evotec shares are owned by company insiders. Comparatively, 9.0% of Qiagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Evotec has a beta of 1.96, indicating that its stock price is 96% more volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.63, indicating that its stock price is 37% less volatile than the S&P 500.

Valuation and Earnings

This table compares Evotec and Qiagen”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Evotec	$891.97 million	0.77	-$117.12 million	N/A	N/A
Qiagen	$2.09 billion	4.36	$424.88 million	$1.95	22.69

Qiagen has higher revenue and earnings than Evotec.

Profitability

This table compares Evotec and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Evotec	-26.20%	-24.93%	-11.35%
Qiagen	19.49%	14.47%	8.34%

Analyst Ratings

This is a summary of current recommendations for Evotec and Qiagen, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Evotec	1	2	2	0	2.20
Qiagen	0	9	4	1	2.43

Evotec currently has a consensus target price of $3.00, indicating a potential upside of 55.44%. Qiagen has a consensus target price of $43.93, indicating a potential downside of 0.73%. Given Evotec’s higher possible upside, equities analysts clearly believe Evotec is more favorable than Qiagen.

Summary

Qiagen beats Evotec on 11 of the 13 factors compared between the two stocks.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health. It has collaboration agreements with SK bioscience, JingXin, Carrick Therapeutics, Sernova, Topas Therapeutics, Exscientia, CONBA Group, Centrexion, Sanofi/NIH, Kazia Therapeutics, Bristol Myers Squibb, Topas Therapeutics, Immunitas, Exscientia, and Bayer; and Inserm, the French National Institute of Health and Medical Research, Lille University Hospital, and Inserm Transfert to identify novel therapeutic targets and diagnostic and prognostic markers in obesity and metabolic diseases, as well as collaboration with CHDI Foundation, Inc.; and a strategic partnership with Dewpoint Therapeutics to advance its portfolio targeting biomolecular condensates as a novel domain for therapeutic intervention towards the clinic, as well as research collaboration with Pfizer for metabolic and infectious diseases. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.